Latham & Watkins Advises on DKK 657.7m (US$100m) Placing by Zealand Pharma

A cross-border capital markets team represents the joint global coordinators, joint bookrunners and co-managers in the offering by the biotechnology company.

June 19, 2020

Latham & Watkins advised Goldman Sachs International, Jefferies International Limited and Danske Bank A/S, the joint global coordinators and joint bookrunners, and Needham & Company and Nordea Danmark, the co-managers in an offering of new shares by Zealand Pharma A/S ("Zealand"). Zealand is a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines. Zealand is listed on Nasdaq Cophenhagen and also has ADRs representing Zealand shares trading on Nasdaq Global Select Market in New York.

The offering was completed through an accelerated book-building process and consisted of 2.68 million new shares, representing 7.25% of Zealand's currently registered share capital, raising DKK 657.7 million (US$100m) in a private placement directed at institutional and professional investors in Denmark and certain other jurisdictions.

Latham’s team was led by Bay Area partner Brian Cuneo and London partners James Inness, and Ryan Benedict, with Bay Area associates Phillip Stoup and Valerie Lau, and London associate Koushik Prasad. Advice was also provided on regulatory matters by Washington, D.C. partner Elizabeth Richards and Bay Area counsel Betty Pang, with Washington, D.C. associate Barrett Tenbarge; and on intellectual property matters by Bay Area partner Christopher Hazuka, with San Diego associate Robert Yeh.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.